Medical product provider, G Medical Innovations Holdings (ASX:GMV)
has secured regulatory approval from the Taiwan Food and Drug Administration for its Prizma device.
The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure vital signs.
Commercial negotiations can now commence with G Medical’s existing distribution and service partner, FCL. G Medical also intends to explore additional partnerships within Taiwan.
CEO and Executive Director Dr Yacov Geva says “[b]eing granted approval by the Taiwan Food and Drug Administration is a tremendous achievement for G Medical. The process has involved rigorous testing, which has outlined the safety and effectiveness of the Prizma device.”
Shares in G Medical Innovations Holdings (ASX:GMV)
are trading 34.6 per cent higher at 18 cents.